News for Citius Pharmaceuticals, Inc. (CTXR)

D. Boral Capital has adjusted its price target for Citius Pharmaceuticals (CTXR), decreasing it from $9 to $6, while maintaining a Buy recommendation for the st

Key Highlights: Citius Pharmaceuticals Inc. (CTXR) launches a strategic direct offering, aiming to raise approximately $6 million through shares and warrant

In recent developments from the stock market, Citius Pharmaceuticals (CTXR) has seen a revision in its price target by analyst Jason Kolbert from D. Boral Capit

PR NewswireCRANFORD, N.J., June 10, 2025 $6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise i

Citius Pharmaceuticals (CTXR) has finalized agreements to sell a total of 4.92 million shares of its common stock, along with short-term warrants for an additio

Citius Pharmaceuticals (CTXR) plans to raise up to $15.8 million through a registered direct offering. The initial offering includes 4,920,000 shares at

On June 9, 2025, Citius Pharmaceuticals (CTXR) remains a focal point for investors as renowned analyst firm D. Boral Capital, led by Jason Kolbert, reiterated i

PR NewswireCRANFORD, N.J., June 9, 2025 Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphomaCRANFORD, N.J., Jun

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), has entered into a distribution services agreement with Cardinal Health (CAH).

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On May 23, 2025, Citius Pharmaceuticals (CTXR) experienced a rating change as Maxim Group, led by analyst Jason McCarthy, downgraded the stock from a "Buy" to a

On May 15, 2025, D. Boral Capital's analyst, Jason Kolbert, announced a continued

\n\nPR NewswireCRANFORD, N.J., May 5, 2025\n\n\n\nCEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ETCRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Cit

H.C. Wainwright has revised its price target for Citius Pharmaceuticals (CTXR), reducing it significantly from $100 to $4. Despite this adjustment, the firm mai

New York-based Marblegate Acquisition Corp. (GATE) is up over 55 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

PR NewswireCRANFORD, N.J., Feb. 14, 2025 CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq:

PR NewswireCRANFORD, N.J., Feb. 14, 2025 CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nas

Citius Pharmaceuticals (CTXR) stock fell 8% in premarket trade, after it announced plans to raise $3M in direct offering. The firm said it will sell 743.5K shar

Citius Pharma secures $3 million in direct offering